Plain-English translation of NCT06071624 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing T cell therapy, a new type of treatment where doctors take your own immune cells, engineer them in the lab to fight your cancer, and put them back into your body. The study is designed for people with chronic myelomonocytic leukemia (a rare blood cancer) that has not responded to standard first-line treatments. Researchers want to see if this medication can help control the disease.
This rare blood cancer is very aggressive and often stops responding to standard treatments, leaving patients with few options. This trial exists to test whether this new treatment approach—using your own enhanced immune cells—might work for people who no longer benefit from conventional therapy.
You likely qualify if…
You likely don't qualify if…
First, you'll have blood drawn and imaging done to confirm your disease status. Then, doctors will perform a procedure called leukapheresis to collect your immune cells from your blood—this is similar to donating blood but takes longer (a few hours). Your cells are sent to a lab to be engineered over several weeks while you may receive mild chemotherapy to keep your disease stable. Once the cells are ready and your disease burden is low enough, you'll receive the engineered cells back as an infusion in the hospital. After that, you'll have frequent blood tests and clinic visits (especially on days 0, 1, 3, 5, 7, 14, and 28) to monitor how the treatment is working and watch for side effects.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United States